ArticleFrontiers in immunology2026
Decoding early lung adenocarcinoma progression by single-cell and spatial transcriptomics reveals a CMA-related prognostic signature.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) progression from adenocarcinoma Methods: We integrated the single-cell transcriptomic dataset GSE189357 and the spatial transcriptomic dataset GSE189487 with bulk transcriptomic data from TCGA-LUAD, GTEx, and the GEO validation cohorts GSE31210 and GSE50081 to characterize CMA-related features during the AIS/MIA-to-IAC progression of LUAD. CMA activity and myeloid remodeling were analyzed at the single-cell and spatial levels. Candidate genes were identified by combining tumor-normal differential expression analysis in TCGA-LUAD with weighted gene co-expression network analysis. Multiple machine learning algorithms were compared to construct and externally validate a prognostic model. Biological and clinical relevance was further assessed through clinicopathological, pathway, immune, cell-cell communication, drug sensitivity, and Results: CMA-related activity showed marked cell-type specificity and spatial heterogeneity during the AIS/MIA-to-IAC progression of LUAD, with the most prominent changes in the myeloid compartment. Myeloid re-clustering revealed enrichment of cDC2 and APOE+ lipid-associated TAMs in IAC, whereas FABP4+ metabolic TAMs and immature neutrophils decreased. By integrating tumor-normal differential expression analysis with weighted gene co-expression network analysis, 122 candidate genes were identified, and a 15-gene CMA-related prognostic signature was established using a random survival forest model. This signature showed robust prognostic stratification in TCGA-LUAD, GSE31210, and GSE50081. The high-risk group had poorer survival, more advanced stage, and enrichment of malignant pathways including GLYCOLYSIS, G2M CHECKPOINT, MTORC1 SIGNALING, E2F TARGETS, and MYC TARGETS. The low-risk group showed higher stromal and immune scores and stronger immune activity. THBS1 signaling was restricted to high-risk epithelial communication, with fibroblasts as the major signal senders. Conclusions: This study characterized CMA-related heterogeneity during LUAD progression from AIS to IAC and established a robust 15-gene prognostic signature. Fibroblast-derived THBS1 signaling and MGP may contribute to the high-risk phenotype and provide insight into early LUAD evolution and risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.